Regenerative Market Entry Target health systems and regenerative medicine networks capitalizing on TheraSkin's FDA-regulated HCT/P status and CMS pass-through approval to accelerate adoption of advanced wound care solutions across hospitals, wound care centers, and outpatient facilities.

Strategic Acquisition Fit Leverage the Solsys medical lineage and portfolio to engage M&A or distribution partnerships with larger medical device players seeking a regenerative skin and wound care portfolio to broaden product offerings and market reach.

High Growth Revenue Position Solsys as a scalable wound care platform with existing revenue in the multi-million range and a funding cushion to support field sales expansion, clinical education, and payer engagement in preparation for broader CMS reimbursement utilization.

Payer Advantage Emphasize CMS pass-through status and non-macerating moisture-rebalancing technology to appeal to payers and procurement teams seeking value-based outcomes, reduced readmissions, and improved healing times in chronic wounds.

Strategic Partnerships Pursue collaborations with tissue banks, regenerative medicine manufacturers, and autograft/bioengineered skin substitutes suppliers to bundle TheraGauze with grafts or adjunctive therapies, expanding installation points and cross-sell opportunities.